<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6720">
    <dcterms:title><![CDATA[<strong>A highly sensitive nanobody-based immunoassay detecting SARS-CoV-2 nucleocapsid protein using all-recombinant reagents</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[COVID-19]]></dcterms:subject>
    <dcterms:subject><![CDATA[PROTEINA DE LA NUCLEOCAPSIDE]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Antigen tests have been crucial for managing the COVID-19 pandemic by identifying individuals infected with SARS-CoV-2. This remains true even after immunity has been widely attained through natural infection and vaccination, since it only provides moderate protection against transmission and is highly permeable to the emergence of new virus variants. For this reason, the widespread availability of diagnostic methods is essential for health systems to manage outbreaks effectively. In this work, we generated nanobodies to the virus nucleocapsid protein (NP) and after an affinity-guided selection identified a nanobody pair that allowed the detection of NP at sub-ng/mL levels in a colorimetric two-site ELISA, demonstrating high diagnostic value with clinical samples. We further modified the assay by using a nanobody-NanoLuc luciferase chimeric tracer, resulting in increased sensitivity (detection limit = 61 pg/mL) and remarkable improvement in diagnostic performance. The luminescent assay was finally evaluated using 115 nasopharyngeal swab samples. Receiver Operating Characteristic (ROC) curve analysis revealed a sensitivity of 78.7% (95% confidence interval: 64.3%-89.3%) and specificity of 100.0% (95% confidence interval: 94.7%-100.0%). The test allows the parallel analysis of a large number of untreated samples, and fulfills our goal of producing a recombinant reagent-based test that can be reproduced at low cost by other laboratories with recombinant expression capabilities, aiding to build diagnostic capacity.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?5246a5ca81aeb900b0acc0265c03abd2" target="_blank"><strong>Segovia de los Santos, Paula</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?86fbaf91aa923439a4e294f1925a27ca" target="_blank"><strong>Padula Roca, Carolina</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Simon, Ximena</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Echaides, C&eacute;sar</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?1c1f29bd240d37882295d2531e2cfdd7bed8462cd28f84bbf32453c0ac9c793ec306557fbabc459cfa8e8564b47d63924c13a8ea78e6df85af1afa01363bc336" target="_blank"><strong>Lassabe, Gabriel</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20" target="_blank"><strong>Gonz&aacute;lez Sapienza, Gualberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Frontiers in immunology, v.14, 2023]]></dcterms:source>
    <dcterms:publisher><![CDATA[Frontiers]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[12 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3389/fimmu.2023.1220477]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6716">
    <dcterms:title><![CDATA[<strong>A highly sensitive nanobody-based ELISA for bovine &beta;-lactoglobulin to classified donated human milk destined to susceptible newborns</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BETA-LACTOGLOBULINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE MATERNA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BANCOS DE LECHE]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The &beta;-lactoglobulin protein from cow&rsquo;s milk is a common allergen present in human milk that leads to serious allergic reactions in susceptible infants. This creates a serious safety issue in Human Milk Banks, and the best practice to assure the safety of susceptible newborns would be to classify the donated human milk according to its content of &beta;-lactoglobulin. To provide a simple and fast assay to detect this molecule in human milk we developed a nanobody-based sandwich ELISA. The capture and detection nanobodies were isolated by phage display from a llama immunized with the antigen using a sequential selection strategy for antibody pair iden tification. This allowed to attain a highly sensitive test with a limit of quantitation of 40 pg/mL and extended lineal range of up to 3000 pg/mL, showing an excellent performance with human milk. For these characteristics, the ELISA developed might be useful for the classification of donated human milk according to their &beta;-lacto globulin content, improving the quality of milk destined to susceptible newborns.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?71934076182f14281ef9fe7e2c7dc381a644339885c1cf0c38160f7dd9fd90b916148bcc01ec448981888590b0b3084a814a46e59aff2122c09d57f1cf176f22" target="_blank"><strong>Rodr&iacute;guez Camejo, Claudio</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?2151545e1e2bcf5a1aed18f0fcbc86f8f572989a1ff4170a7081b84aaee68c3f0c594002567678df9a2ad53f09c41af0654f6be4d057bda841a03a8994b48e31" target="_blank"><strong>Delfin Riela, Triana</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cvsni/?urlId=0714ab9cf73af9870ec8809b325b44115e7a8c32a7bffc5b0260762ba5347b07fa4dc1efff263fa6245889f68b031f22fc09f7dd37fb84c74004165d1dca6005&amp;convocatoria=21&amp;formato=html" target="_blank"><strong>Rossotti, Mart&iacute;n A.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Puyol, Arturo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Echaides, C&eacute;sar</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?e48336f406343f48c858e7403983e63cc46d4bcc33267754f0e951102827dcb148a4da125f875269753f952843d446507c27d521c2053a1d384354c62d730f2c" target="_blank"><strong>Hern&aacute;ndez, Ana</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez Sapienza, Gualberto</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Food Control, v.153, 2023. --e109910]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[8 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.foodcont.2023.109910]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6656">
    <dcterms:title><![CDATA[<strong>Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIRUS DEL BOSQUE SEMLIKI]]></dcterms:subject>
    <dcterms:subject><![CDATA[SFV]]></dcterms:subject>
    <dcterms:subject><![CDATA[ALFAVIRUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[PD-1]]></dcterms:subject>
    <dcterms:subject><![CDATA[PD-L1]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOTERAPIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[CANCER]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Despite the success of immune checkpoint blockade for cancer therapy, many patients do not respond adequately. We aimed to improve this therapy by optimizing both the antibodies and their delivery route, using small monodomain antibodies (nanobodies) delivered locally with a self-amplifying RNA (saRNA) vector based on Semliki Forest virus (SFV). We generated nanobodies against PD-1 and PD-L1 able to inhibit both human and mouse interactions. Incorporation of a dimerization domain reduced PD-1/PD-L1 IC50 by 8- and 40-fold for anti- PD-L1 and anti-PD-1 nanobodies, respectively. SFV viral particles expressing dimeric nanobodies showed a potent antitumor response in the MC38 model, resulting in &gt;50% complete regressions, and showed better therapeutic efficacy compared to vectors expressing conventional antibodies. These effects were also observed in the B16 melanoma model. Although a short-term expression of nanobodies was observed due to the cytopathic nature of the saRNA vector, it was enough to generate a strong proinflammatory response in tumors, increasing infiltration of NK and CD8+ T cells. Delivery of the SFV vector expressing dimeric nanobodies by local plasmid electroporation, which could be more easily translated to the clinic, also showed a potent antitumor effect.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Silva Pilipich, Noelia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Blanco, Ester</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Lozano, Teresa</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Martisova, Eva</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Igea, Ana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Herrador-Ca&ntilde;ete, Guillermo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ballesteros-Briones, Mar&iacute;a Cristina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gorraiz, Marta</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sarri&oacute;n, Patricia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez Sapienza, Gualberto</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Lasarte, Juan Jos&eacute;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Vanrell, Luc&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Smerdou, Cristian</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Cancer Letters v. 561, 2023. -- e216139]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[13 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.canlet.2023.216139]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6409">
    <dcterms:title><![CDATA[<strong>Induction of antigen-specific tolerance by nanobody&ndash;antigen adducts that target class-II major histocompatibility complexes</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTIGENOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HISTOCOMPATIBILIDAD]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDADES AUTOINMUNES]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2021]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>The association of autoimmune diseases with particular allellic products of the class-II major histocompatibility complex<br />(MHCII) region implicates the presentation of the offending self-antigens to T cells. Because antigen-presenting cells are<br />tolerogenic when they encounter an antigen under non-inflammatory conditions, the manipulation of antigen presentation may induce antigen-specific tolerance. Here, we show that, in mouse models of experimental autoimmune encephalomyelitis, type 1 diabetes and rheumatoid arthritis, the systemic administration of a single dose of nanobodies that recognize MHCII molecules and conjugated to the relevant self-antigen under non-inflammatory conditions confers long-lasting protection against these diseases. Moreover, co-administration of a nanobody&ndash;antigen adduct and the glucocorticoid dexamethasone, conjugated to the&nbsp;nanobody via a cleavable linker, halted the progression of established experimental autoimmune encephalomyelitis in symptomatic mice and alleviated their symptoms. This approach may represent a means of treating autoimmune conditions.</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Pishesha, Novalia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Harmand, Thibault</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Smeding, Liyan Y.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ma, Weiyi</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ludwing, Leif S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Janssen, Robine</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Islam, Ashraful</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Xie, Yushu J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fang, Tao</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>McCaul, Nicholas</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pinney III, Wiliam</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sugito, Harun R.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cvsni/?urlId=0714ab9cf73af9870ec8809b325b44115e7a8c32a7bffc5b0260762ba5347b07fa4dc1efff263fa6245889f68b031f22fc09f7dd37fb84c74004165d1dca6005&amp;convocatoria=21&amp;formato=html" target="_blank"><strong>Rossoti, Martin A.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20" target="_blank"><strong>Gonz&aacute;lez Sapienza, Gualberto</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ploegh, Hidde L.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Nature Biomedical Engineering, 2021.]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2021]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span id="docs-internal-guid-80b53838-7fff-331c-3ee1-4cf13e92c83e"><span>10.1038/s41551-021-00738-5&nbsp; </span></span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6209">
    <dcterms:title><![CDATA[<strong>Highly Sensitive Detection of Zika Virus Nonstructural Protein 1 in Serum Samples by a Two-Site Nanobody ELISA</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ZIKA-VIRUS
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOENSAYO ELISA
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOCUERPOS
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[2020
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The Zika virus was introduced in Brazil in 2015 and, shortly after, spread all over the Americas. Nowadays, it remains present in more than 80 countries and represents a major threat due to some singularities among other flaviviruses. Due to its easy transmission, high percentage of silent cases, the severity of its associated complications, and the lack of prophylactic methods and eective treatments, it is essential to develop reliable and rapid diagnostic tests for early containment of the infection. Nonstructural protein 1 (NS1), a glycoprotein involved in all flavivirus infections, is secreted since the beginning of the infection into the blood stream and has proven to be a valuable biomarker for the early diagnosis of other flaviviral infections. Here, we describe the development of a highly sensitive nanobody ELISA for the detection of the NS1 protein in serum samples. Nanobodies were selected from a library generated from a llama immunized with Zika NS1 (ZVNS1) by a two-step high-throughput screening geared to identify the most sensitive and specific nanobody pairs. The assay was performed with a sub-ng/mL detection limit in the sera and showed excellent reproducibility and accuracy when validated with serum samples spiked with 0.80, 1.60, or 3.10 ng/mL of ZVNS1. Furthermore, the specificity of the developed ELISA was demonstrated using a panel of flavivirus&rsquo; NS1 proteins; this is of extreme relevance in countries endemic for more than one flavivirus. Considering that the nanobody sequences are provided, the assay can be reproduced in any laboratory at low cost, which may help to strengthen the diagnostic capacity of the disease even in low-resource countries.
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Delfin Riela, Triana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rossotti, Mart&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alvez-Rosado, Romina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leizagoyen, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez-Sapienza, Gualberto</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biomolecules v. 10, 2020. -- p. 1-14.--e 1652
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:publisher>
    <dcterms:date><![CDATA[2020
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong> (Por favor lea este aviso antes de abrir los documentos u objetos)<strong> La legislaci&oacute;n uruguaya protege el derecho de autor </strong>sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006) ADVERTENCIA - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[Pdf
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.3390/biom10121652
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6202">
    <dcterms:title><![CDATA[<strong>Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[INMUNOTERAPIA
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[TERAPIA DE GENES
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[CANCER
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOCUERPOS
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD ANTICANCERIGENA
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[2020
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:subject>
    <dcterms:creator><![CDATA[<strong>Silva-Pilipich, Noelia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Martisova, Eva</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ballesteros Briones, Mar&iacute;a Cristina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hervas-Stubbs, Sandra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Casares, Noelia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez Sapienza, Gualberto</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Smerdou, Cristian</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Vanrell, Luc&iacute;a</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biomedicines v. 8, 2020. -- p. 1-19.--e562
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:publisher>
    <dcterms:date><![CDATA[2020
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong> (Por favor lea este aviso antes de abrir los documentos u objetos)<strong> La legislaci&oacute;n uruguaya protege el derecho de autor </strong>sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006) ADVERTENCIA - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[Pdf
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.3390/biomedicines8120562
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>
<div id="sconnect-is-installed" style="display: none;">2.11.0.0</div>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5975">
    <dcterms:title><![CDATA[Structure and specificity of several triclocarban-binding single domain camelid antibody fragments]]></dcterms:title>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESTRUCTURA CRISTALINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRICLOCARBAN]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2019]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The variable VHH domains of camelid single chain antibodies have been useful in numerous biotechnology applications due to their simplicity, biophysical properties, and abilities to bind to their cognate antigens with high affinities and specificity. Their interactions with proteins have been well-studied, but considerably less work has been done to characterize their ability to bind haptens. A high-resolution structural study of three nanobodies (T4, T9, and T10) which have been shown to bind triclocarban (TCC, 3-(4-chlorophenyl)-1-(3,4-dichlorophenyl)urea) with near-nanomolar affinity shows that binding occurs in a tunnel largely formed by CDR1 rather than a surface or lateral binding mode seen in other nanobody-hapten interactions. Additional significant interactions are formed with a non-hypervariable loop, sometimes dubbed "CDR4". A comparison of apo and holo forms of T9 and T10 shows that the binding site undergoes little conformational change upon binding of TCC. Structures of three nanobody-TCC complexes demonstrated there was not a standard binding mode. T4 and T9 have a high degree of sequence identity and bind the hapten in a nearly identical manner, while the more divergent T10 binds TCC in a slightly displaced orientation with the urea moiety rotated approximately 180&deg; along the long axis of the molecule. In addition to methotrexate, this is the second report of haptens binding in a tunnel formed by CDR1, suggesting that compounds with similar hydrophobicity and shape could be recognized by nanobodies in analogous fashion. Structure-guided mutations failed to improve binding affinity for T4 and T9 underscoring the high degree of natural optimization.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Tabares da Rosa, Sof&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wogulis, Linda A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wogulis, Mark D.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>Gonz&aacute;lez Sapienza, Gualberto.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wilson, David K.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Molecular Recognition v. 32, no. 1, 2019. -- p. 1-9.--e2755]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2019]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1002/jmr.2755]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5904">
    <dcterms:title><![CDATA[<strong>Oriented functionalization of magnetic beads with in vivo biotinylated nanobodies for rapid MALDI-TOF ultrasensitive quantitation of microcystins in biological samples</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[CIANOTOXINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2019]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Here we present a new analytical method where immunoconcentration of the analyte is coupled to quantitative matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) analysis allowing in minutes the identification and highly sensitive quantitation of microcystins (MCs) as model targets. The key element is a site-specific in vivo biotinylated nanobody of broad cross-reactivity with microcystins. The single biotin moiety at the C-terminus and the small size of the nanobody (15 kDa) enable its oriented and tightly packed immobilization on magnetic beads, providing a highly efficient capture of the toxin. The binding capacity of the bioadsorbent is partially loaded with an easily synthesized internal standard for MS quantitation. After capture, the beads are directly dispensed on the MALDI-TOF MS target enabling the identification and sensitive quantitation of the microcystin (MC) congeners. Since salts and contaminants are removed during the concentration step, no cleanup or other sample treatments are needed. The method was validated with a large number of water and serum samples with excellent precision and recovery at quantitation limits of 0.025 &mu;g/L of MC.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=551c5710da6933c1089ec0d5955dcdc6f8139412c73650c95b82a2b3b02388a3247ceadce7333c784ca076abeafe679c38b5f2272687b8ab5cc950f03394f2a7&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>P&iacute;rez-Schirmer, Macarena</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=76fda5e876d7838a885399f5cef02e0d379f384ffe6daa3cb23af35c02ec6f7f1e120c2bddda0b94b93ca0683d4b038a08132b4d8ad1bbe4dab743b47bb1df5e&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>Brena, Beatriz M.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>Gonz&aacute;lez Sapienza, Gualberto.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Analytical Chemistry&nbsp; v. 91, no. 15, 2019. --p. 9925-9931]]></dcterms:source>
    <dcterms:publisher><![CDATA[American Chemical Society]]></dcterms:publisher>
    <dcterms:date><![CDATA[2019]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1021/acs.analchem.9b01596]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3809">
    <dcterms:title><![CDATA[<strong>Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ENSAYO INMUNO ENZIMATICO]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOTERAPIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOCUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS TERAPEUTICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2015]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Recombinant single domain antibodies (nanobodies) constitute an attractive alternative for the production of neutralizing therapeutic agents. Their small size warrants rapid bioavailability and fast penetration to sites of toxin uptake, but also rapid renal clearance, which negatively affects their performance. In this work, we present a new strategy to drastically improve the neutralizing potency of single domain antibodies based on their fusion to a second nanobody specific for the complement receptor CD11b/CD18 (Mac-1). These bispecific antibodies retain a small size (~30 kDa), but acquire effector functions that promote the elimination of the toxin-immunocomplexes. The principle was demonstrated in a mouse model of lethal toxicity with tetanus toxin. Three anti-tetanus toxin nanobodies were selected and characterized in terms of overlapping epitopes and inhibition of toxin binding to neuron gangliosides. Bispecific constructs of the most promising monodomain antibodies were built using anti Mac-1, CD45 and MHC II nanobodies. When co-administered with the toxin, all bispecific antibodies showed higher toxin-neutralizing capacity than the monomeric ones, but only their fusion to the anti-endocytic receptor Mac-1 nanobody allowed the mice to survive a 10-fold lethal dose. In a model of delayed neutralization of the toxin, the anti- Mac-1 bispecific antibodies outperformed a sheep anti-toxin polyclonal IgG that had shown similar neutralization potency in the co-administration experiments. This strategy should have widespread application in the development of nanobody-based neutralizing therapeutics, which can be produced economically and more safely than conventional antisera.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rossotti, Mart&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=67c04f6a200d5de027ddb6804d7bae5f" target="_blank"><strong>Gonz&aacute;lez Techera, Andr&eacute;s</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Guarnaschelli, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Yim, Lucia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Camacho, Ximena</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fern&aacute;ndez Silveira, Marcelo.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cabral, Pablo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leizagoyen, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chabalgoity Jose A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=7ee0def1187be47e0710e877d9768b5a" target="_blank"><strong>Gonz&aacute;lez-Sapienza, Gualberto G</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[MAbs v. 7, no. 5, 2015. -- p. 820-828]]></dcterms:source>
    <dcterms:publisher><![CDATA[Taylor &amp; Francis Group]]></dcterms:publisher>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1080/19420862.2015.1068491]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
